Dr. Nora Chokr, MD

Dr. Chokr practices at NewYork-Presbyterian/Weill Cornell Medical Center in New York, New York, part of NewYork-Presbyterian Hospital.

Dr. Chokr's NPI, 1831553262, was assigned on April 12, 2016. Dr. Chokr graduated from American University of Beirut Faculty of Medicine in 2015. Dr. Chokr holds New York license 318820.

Dr. Chokr's primary practice is NewYork-Presbyterian/Weill Cornell Medical Center, at 525 East 68th Street, New York, NY 10065 in New York County. The practice phone is (212) 746-5454.

Dr. Chokr's primary practice is NewYork-Presbyterian/Weill Cornell Medical Center in New York, New York, part of NewYork-Presbyterian Hospital. Dr. Chokr is also affiliated with Tisch Hospital. The medical group on file is NYU Langone Orthopedic Surgery Associates. Dmand AI also links Dr. Chokr to 2 more clinical labs, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Chokr practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Chokr's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Chokr is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Chokr's licenses on file in 2 states: New York and Connecticut.

CMS data shows 499 Medicare services from Dr. Chokr across 5 procedure codes in 2024, for 61 Medicare patients. Medicare paid $44,867 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 61 Medicare patients who saw Dr. Chokr in 2024. The largest group is 65 to 74, with 40 patients. 75% of them have high blood pressure, and 69% have high cholesterol. 21% are also on Medicaid. Their average risk score is 4.52, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Chokr's median patient age at 69, with 46% women.

In 2024, Dr. Chokr wrote 37 Medicare Part D claims. 65% of them were for generic drugs. CMS names the drug for 12 of them, across 1 drug with 11 or more claims each, at $347 in total drug cost. In 2020, CMS named 11 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Chokr for performance year 2024, reported through an alternative payment model (APM). Dr. Chokr accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 12 papers to Dr. Chokr, published from 2017 to 2025. 2023 was the busiest year, with 3. The most frequent topics are Hematopoietic Stem Cell Transplantation, Immunotherapy, Adoptive and Myelodysplastic Syndromes. Dr. Chokr has published most often in Bone Marrow Transplant. Dr. Chokr's most frequent co-authors are Mohammad S. Alhomoud, Tsiporah B. Shore, MD and Samuel J. Yamshon, MD.

CMS Open Payments shows 38 general payments to Dr. Chokr from 8 drug and device companies from 2021 to 2025. Consulting fees make up the largest share, 71% of the total. Incyte Corporation paid the most, $9,150.

Dr. Chokr graduated from American University of Beirut Faculty of Medicine in 2015.

Dr. Chokr is in network with 16 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.